Solventum detailed its 2025-2028 growth strategy, reaffirmed its 2025 guidance, and reported Q4 earnings that topped expectations with strong sales and EPS.
Over the last six months, Thermo Fisher shares have sunk to $508.90, producing a disappointing 17.1% loss - worse than the S&P 500’s 1.2% drop. This might have investors contemplating their next move.
David Kostin, the Chief U.S. Equity Strategist of Goldman Sachs (NYSE: GS), has revised his earnings growth forecast, citing a weaker economic outlook, and highlighted a shift in market trends.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Thermo Fisher (NYSE:TMO) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSE:RVTY) and the best and worst performers in the research tools & consumables industry.
Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher.
Thermo Fisher will acquire Solventum's Purification & Filtration business for $4.1 billion, expanding its bioproduction portfolio with expected long-term growth.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But near-term speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.
This has capped returns as the industry’s six-month gain of 1.2% has lagged the S&P 500’s 12.8% climb.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
